Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

psoriasis

Novartis building

Novartis’ secukinumab tops Enbrel in psoriasis study

Phase III results show the antibody is more effective than Amgen/Pfizer's blockbuster

- PMLiVE

Merz pulls out of race for Obagi Medical

Leaves Valeant open to complete takeover

- PMLiVE

Battle lines drawn as Valeant ups Obagi bid

Hits back against Merz offer

- PMLiVE

Merz offers $385m to trump Valeant’s bid for Obagi

Could spark bidding war for dermatology specialist

- PMLiVE

Celgene’s apremilast set for 2013 filing

Pharma company releases positive phase III results for psoriasis candidate

- PMLiVE

IQWiG knocks back Almirall’s Eklira

Decides added benefit of COPD drug is not proven

Forest Labs launches COPD drug Tudorza in US

Enters a market dominated by Boehringer and Pfizer's Spiriva and GSK's Advair

Almirall appoints first woman to the board

Karin Louise Dorrepaal will serve as an independent board member

- PMLiVE

UCB’s chair Gerhard Mayr joins Almirall board

He becomes an independent director of the Spanish pharma company

Janssen adds Astellas JAK inhibitor to its immunology portfolio

Licenses oral rheumatoid arthritis and psoriasis candidate ASP015K

Novartis drug effective in hard-to-treat psoriasis

Secukinumab to commence phase III trials

Almirall’s IBS drug Constella backed by CHMP

On track to become the first drug specifically approved for the condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links